PRECIPIO INC 2026 Q2
Earnings Overview & AI Insights

Earnings Performance

Summary of Financial Performance:
Precipio reported Q2 revenue of just over $7.0 million, up from about $6.7 million in Q1 and approximately $5.7 million year over year, representing roughly 22% YoY growth. Pathology revenue was about $6.1 million, modestly higher sequentially, while product revenue rose to about $900,000 from roughly $660,000 in Q1, up 35% and about 21% above the prior record. Adjusted EBITDA improved to about $400,000 from negative $200,000 in Q1, helped by higher revenue and lower stock-based compensation. The company also generated about $700,000 in operating cash flow and ended the quarter with more than $3 million in cash.

Company Outlook & Strategy:
Management was upbeat and emphasized that Q2 validated the company’s “flywheel” model, where pathology operations help identify real clinical problems and support product development, while products create a more scalable revenue stream. For the second half of 2026, the company expects continued revenue growth, further expansion in product sales, conversion of pipeline into active accounts, and greater operating leverage translating into EBITDA and cash flow. Management stressed execution, commercialization, and continued innovation as core priorities.

Key Industry Trends:
The call highlighted a major unmet need in AML diagnostics, where standard molecular results can take 10–14 days despite the urgency of treatment decisions. Precipio positioned its rapid AML assay as a one-day solution addressing a clinically critical gap. Management also noted growing interest from domestic and international customers, along with the importance of marketing collaborations and clinical studies in biotech commercialization.

Operational Highlights:
The company added approximately 10 new distributor reps in Q2, identified over 25 new qualified customers, and held or scheduled more than 30 customer meetings during the quarter. Management said it is still refining how to work effectively with major distributors, including Thermo Fisher, McKesson, Medline, and Cardinal, but pipeline growth was described as significant. The pathology division continues to serve as the clinical infrastructure and recurring revenue base supporting product development.

Challenges & Risks:
Management acknowledged prior concerns about product revenue timing and explained that quarter-to-quarter variability can be driven by shipment timing rather than demand weakness. They also noted the challenge of scaling through large distributor relationships, which require different commercial approaches and take time to optimize. More broadly, management implied that growth must continue to convert from pipeline into realized revenue to sustain momentum.

Key Analyst Questions & Responses:
The only analyst question focused on unusually heavy trading volume in the stock. Management said it did not have visibility into the source of the trades, suggested the volume may reflect increased investor relations activity and conference participation, and also pointed to possible algorithmic trading. No operational or financial follow-up questions were asked.